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INTRODUCTION: Epstein-Barr virus exposure appears to be an environmental trigger for rheumatoid arthritis that
interacts with other risk factors. Relationships among anti-cyclic citrullinated peptide antibodies, the shared
epitope, and smoking status have been observed in patients with rheumatoid arthritis from different populations.
OBJECTIVE: To perform an association analysis of anti-Epstein-Barr nuclear antigen-1 antibodies, anti-cyclic
citrullinated peptide antibodies, the shared epitope, and smoking status in Brazilian patients with rheumatoid
arthritis.
METHODS: In a case-control study, 140 rheumatoid arthritis patients and 143 healthy volunteers who were matched
for age, sex, and ethnicity were recruited. Anti-Epstein-Barr nuclear antigen-1 antibodies and anti-cyclic
citrullinated peptide antibodies were examined using an enzyme-linked immunosorbent assay, and shared epitope
alleles were identified by genotyping. Smoking information was collected from all subjects. A comparative analysis
of anti-Epstein-Barr nuclear antigen-1 antibodies, anti-cyclic citrullinated peptide antibodies, the shared epitope,
and smoking status was performed in the patient group. Logistic regression analysis models were used to analyze
the risk of rheumatoid arthritis.
RESULTS: Anti-Epstein-Barr nuclear antigen-1 antibodies were not associated with anti-cyclic citrullinated peptide
antibodies, shared epitope alleles, or smoking status. Anti-cyclic citrullinated peptide antibody positivity was
significantly higher in smoking patients with shared epitope alleles (OR=3.82). In a multivariate logistic regression
analysis using stepwise selection, only anti-cyclic citrullinated peptide antibodies were found to be independently
associated with rheumatoid arthritis (OR=247.9).
CONCLUSION: Anti-Epstein-Barr nuclear antigen-1 antibodies did not increase the risk of rheumatoid arthritis and
were not associated with the rheumatoid arthritis risk factors studied. Smoking and shared epitope alleles were
correlated with anti-cyclic citrullinated peptide-antibody-positive rheumatoid arthritis. Of the risk factors, only anti-
cyclic citrullinated peptides antibodies were independently associated with rheumatoid arthritis susceptibility.
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INTRODUCTION
Rheumatoid arthritis (RA) is an inflammatory autoimmune
disease with a pathogenesis that is not fully understood. The
pathophysiology of RA is complex and multifactorial and
involves both genetic and environmental factors. Many studies
have demonstrated the importance of certain human leuko-
cyte antigens (HLA) molecules that contain the shared epitope
(SE) as the major genetic risk factor for RA. Nevertheless,
genetic factors fail to completely explain the occurrence of
RA.1,2
In addition, antibodies to cyclic citrullinated peptides (anti-
CCP) are highly specific predictors of RA. Anti-CCP have
been observed many years prior to disease onset, indicating an
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important role for them in the development of RA. An
association between the positivity of anti-CCP and the
presence of the SE in RA has been reported by numerous
researchers. The presence of SE alleles appears to be a risk
factor related to anti-CCP production.1,3 Interactions between
tobacco exposure and SE status in anti-CCP-positive patients
have been demonstrated by several studies, whereas neither
smoking nor SE status confers an increased risk of developing
anti-CCP negative RA.4-10
Among other environmental factors, infectious agents,
most notably viruses, have long been suspected of promot-
ing the development of RA and other autoimmune
diseases.11-13 Links between Epstein-Barr virus (EBV) and
RA have been a focus of research for the last three decades.
Studies have demonstrated that EBV is a potent B-cell
stimulator, antibodies in RA cross-react with EBV nuclear
antigens, and EBV glycoproteins share sequence similarities
with the HLA-DRB1 SE. These viral properties support the
theory that EBV is a strong risk factor for RA.12-15
It has been observed that the levels of some anti-EBV
antibodies (anti-EBNA, anti-VCA, and anti-EA) are higher in
RA patients than in controls.16,17 In particular, Epstein-Barr
nuclear antigen-1 (EBNA-1) contains glycine/alanine sequen-
ces that constitute a dominant EBNA-1 epitope against which
specific reactivity has been demonstrated.18,19 An antibody
against this EBNA-1 sequence also reacted with a protein
expressed by synovial lining cells in RA patients.20 Identical
glycine/alanine repeat sequences of EBNA-1 are also present
in collagen, cytokeratin, and actin.21
Many studies have suggested that some RA risk factors
are highly associated with EBV in the complex etiopatho-
geny of RA. Among the antibodies against EBV, anti-EBNA-
1 appears to be the most prominent in the interactions with
other risk factors. In the present study, we evaluated
associations between anti-EBNA-1, anti-CCP, shared epi-
tope alleles, and smoking status in Brazilian RA patients.
METHODS AND MATERIALS
Patients and controls
A total of 140 RA Brazilian patients (including 122 females)
aged 25-82 years (mean = 54.24 years), comprising 74
Caucasians, 20 Blacks, and 46 Mulattoes were evaluated at
the University of Campinas Teaching Hospital in Brazil. All
the patients fulfilled the 1987 RA revised criteria of the
American College of Rheumatology. For the control group,
we screened 143 healthy individuals who were matched for
age, sex, and ethnicity and had no personal or family history
of autoimmune disease. Smoking exposure was measured in
pack-years, and all subjects were classified as never smoker,
past smoker or current smoker. Clinical information was
collected using a questionnaire at the time of enrollment.
This study was approved by the ethics committee of the
University of Campinas, Brazil, and informed consent was
obtained from all patients and controls.
Serology and genotyping
Anti-EBNA1 antibodies were analyzed using an enzyme-
linked immunosorbent assay (ELISA) kit containing synthetic
peptides (ETI-EBNA-G, DiaSorin, Saluggia, Italy). Anti-CCP
antibodies were determined by ELISA (QUANTA Lite CCP3
IgG, Inova Diagnostics Inc., USA). Rheumatoid factor was
evaluated by a nephelometric immunoassay (BN ProSPec
System, Siemens, Marburg, Germany). All assays were
performed according to the manufacturers’ instructions.
HLA-DRB1 typing was undertaken by polymerase chain
reaction (PCR), using specific primers and hybridization
with sequence-specific oligonucleotides, as previously
described.22 HLA-DRB1*01, HLA-DRB1*04, and HLA-
DRB1*10 were the SE alleles studied.5 Patients carrying
zero, one, or two alleles of SE were classified as SE2/2,
SE+/2, or SE +/+, respectively.
Statistical analysis
The chi-squared and Fisher’s exact tests were used to
compare categorical variables between the groups. The
differences between the mean or median values of two
groups were analyzed using the Mann-Whitney test. The
Kruskal-Wallis test was used when the subjects were
separated into three or more groups. To evaluate RA risk,
we calculated odds ratios (OR) with 95% confidence
intervals (CI). A logistic regression analysis with univariate
and multiple models was used with stepwise variable
selection. The significance level for statistical tests was set at
5% (p,0.05). All statistical analyses were performed using
SAS (Statistical Analysis System) software for Windows,
version 9.1.3 (SAS Institute Inc., Cary, NC, USA).
RESULTS
Patient and control characteristics
The demographic, clinical, and laboratory characteristics
of the RA cases and matched controls are listed in Table 1.
Anti-EBNA-1, anti-CCP, SE status, and smoking
status in patients and controls
The rates of anti-EBNA-1 and anti-CCP positivity, as well
as the mean antibody levels detected using these assays,
along with the percentages related to SE status and smoking
status in the two groups, are listed in Table 2. No significant
differences were observed between the patient group and
the control group in terms of the positivity and the mean
levels of anti-EBNA-1 antibodies. The positivity and mean
levels of anti-CCP antibodies were significantly higher in
the patients than in the controls (p,0.001). The presence of
the SE alleles (SE+/2 and SE+/+) and a smoking history
of at least 15 pack-years were significantly higher in the
patients than in the controls (p,0.001 and p= 0.003,
respectively).
Table 1 - Demographic, clinical, and laboratory
characteristics.
Variables
RA patients
(n = 140) Controls (n = 143)
Women, n (%) 122 (87.1) 123 (86.0)
Ethnicity, n (%)
Caucasian
74 (52.9) 83 (58.0)
Mulattoes 46 (32.9) 39 (27.3)
Black 20 (14.3) 21 (14.7)
Age (years) 54.2¡11.3 55.8¡13.4
Duration of disease (years) 10.2¡6.9 NA
RF-positive, n (%) 111 (79.3) ND
Data are reported as numbers of subjects with percentages or Mean ¡
Standard Deviation (SD) in parentheses. RA= Rheumatoid Arthritis;
RF = Rheumatoid Factor; NA= not applicable; ND= not determined.
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Anti-EBNA-1 profile according to anti-CCP, SE
status, and smoking status in patients
Anti-EBNA-1 levels were standardized in quartiles (1 =
,63.71 U/ml; 2 = 63.71-125.26 U/ml; 3 = 125.27-333.44 U/ml;
4 = $333.45 U/ml). No significant differences were found in
the distribution of anti-EBNA-1 antibodies according to anti-
CCP positivity, SE status, or smoking status (Figure 1).
Anti-CCP profile according to SE status and smoking
status in patients
Although it was not significant, there was a trend for
patients with higher levels of anti-CCP to carry SE alleles
(p= 0.059). Smokers had significantly higher levels of anti-
CCP (p= 0.018). SE carriers and smoking patients had a
significantly higher risk of being positive for anti-CCP
(Figure 2, OR = 3.82; 95% CI = 1.28211.40; p= 0.016).
Anti-EBNA1, anti-CCP, SE status, and smoking status
in RA risk
The univariate logistic regression analysis showed that
anti-CCP positivity carried a highly significant RA risk
(p,0.001; OR = 247.49). The presence of one or two SE alleles
increased the risk of RA 1.90-fold (p= 0.012) and 4.67-fold
(p= 0.001), respectively. A smoking history of 15 or more
pack-years led to a 3.17-fold increased risk of RA (p= 0.001).
Anti-EBNA-1 levels were not found to be a risk factor for
RA in this model.
In the multivariate logistic regression analysis with
stepwise selection, anti-CCP was the only selected variable
that was independently associated with RA.
DISCUSSION
There is increasing evidence of the roles of a number of
environmental factors, including viruses exposure and
smoking, in the pathogenesis of RA. EBV has been studied
for many decades; however, it remains unclear how its
interactions with other RA risk factors develop. In 1976,
Alpsaugh and Tan observed a higher serologic reactivity to
the nuclei of EBV-infected B cells in RA patients than in the
controls.23 The target B cell antigen was named ‘‘rheumatoid
arthritis nuclear antigen’’ (RANA). Reactivity to RANA was
not observed in uninfected B cells and was not influenced by
the HLA-DR phenotype or the presence of rheumatoid factor.
Subsequently, it was established that RANA was, in fact, the
same molecule as EBNA-1. The QKRAA sequence present in
HLA-DRB1*0401 shares sequence homology with EBV gp110
protein, a target of the immune response to infection.24
Deblon et al. demonstrated that RA patients who carried the
SE had a stronger humoral response to EBNA-1 than did SE-
negative RA patients.25 These data are conflicting but suggest
that EBV infection is related to the presence of HLA-DR
molecules that contain the SE.
The anti-citrulline immune response is strongly involved
in RA etiology, and anti-citrulline antibodies can precede
RA development by several years. Anti-CCP antibodies are
highly specific and are considered a valuable disease
marker and a strong risk factor for RA. A gene-environment
interaction among anti-CCP antibodies, SE status, and
smoking has been observed in several studies. The presence
of HLA-DR SE only confers a risk of RA to patients who are
positive for anti-CCP.1,10,26,27 Smoking is associated with the
increased presence of citrulline-modified proteins in geneti-
cally predisposed individuals who carry HLA-DR SE
alleles.8-10 In this study, we did not perform the HLA-
DRB1 subtyping to identify HLA-DR SE alleles, since
Lundstro¨m et al. observed that interactions of SE status
with anti-CCP antibodies and smoking were independent of
HLA-DRB1 subtyping and occurred with *01, *04, and *10
groups, regardless of fine specificity.5
EBV antigens can also undergo citrullination, thus
becoming targets of anti-CCP. Antibodies to citrullinated
EBV peptides have been identified in sera from RA patients,
and the viral-citrullinated-peptide antibody levels of these
patients correlated with their anti-CCP levels.28 A relation-
ship between EBV and citrullinated peptides was supported
by the observation that anti-citrulline antibodies reacted
with deiminated EBNA-1.29 Toussirot and Roudier sug-
gested that EBV should be considered as an environmental
factor associated with anti-CCP production, just as smoking
is associated with anti-CCP development in RA patients.15
It remains unknown how EBV influences the risk of
developing RA. Anti-EBNA-1 antibodies are increased in
individuals who are exposed to EBV and remain increased
for a lifetime. Multiple sclerosis (MS) is a good example of
an autoimmune disease for which anti-EBNA-1 antibodies
have been shown to be a strong risk factor. Interestingly,
this risk is increased by smoking but is independent of the
MS susceptibility HLA-DR15 allele.30,31 In the present study,
we showed a high positivity of anti-EBNA-1 in both patients
and controls, and there was no association between anti-
EBNA-1 levels and anti-CCP levels, SE status, or smoking
status in RA patients. The relative risk for RA was not
increased in patients with higher levels of anti-EBNA-1.
Thus, we have demonstrated that anti-EBNA-1 serology
cannot evaluate the interactions between EBV and the most
well-known RA risk factors. Further studies could assess the
role of EBV in RA pathogenesis. The accurate quantification
of EBV by real-time polymerase chain reaction and the
evaluation of antibodies to viral citrullinated peptides are
promising techniques that could aid in this process.28,32,33
Brazil has a heterogeneous population with a distinct
genetic profile that has been influenced by various racial and
ethnic groups, predominantly Africans and Europeans. As
reported in more homogeneously Caucasian populations5-8,
Table 2 - Comparative analysis of anti-EBNA-1, anti-CCP,
SE status, and smoking status in RA patients and controls.
RA patients Controls p-value
Anti-EBNA1-positive, n (%) 127 (90.7) 130 (90.9) 0.955
Mean anti-EBNA1 levels (U/ml) 246.1 277.1 0.111
Anti-CCP-positive, n (%) 109 (77.9) 2 (1.4) ,0.001
Mean anti-CCP levels (U/ml) 117.0 6.8 ,0.001
Shared epitope status, n (%)
SE 2/2 52 (37.1) 81 (56.6)
,0.001
SE +/2 67 (47.9) 55 (38.5)
SE +/+ 21 (15.0) 7 (4.9)
Smoking status, n (%)
Non-smokers 82 (58.6) 107 (74.8)
0.003
,15 pack-years 24 (17.1) 22 (15.4)
$15 pack-years 34 (24.3) 14 (9.8)
Data are reported as numbers of subjects with percentages or mean levels
in parentheses. RA=Rheumatoid Arthritis; Anti-EBNA-1 = Anti-Epstein-
Barr Nuclear Antigen 1 Antibodies; Anti-CCP = Anti-Cyclic Citrullinated
Antibodies; SE = Shared Epitope; p= significance based on Pearson’s
chi-squared or Mann-Whitney test. Differences were considered to be
significant at p,0.05.
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we showed that SE alleles and tobacco exposure are related to
anti-CCP antibodies in RA patients. Several previous studies
observed these same relationships in Brazilian RA
patients.34,35
In this study, we demonstrated the contributions of anti-
CCP antibodies, the presence of the SE, and smoking history to
RA risk. However, through a multivariate logistic regression
analysis, we showed of the risk factors, only anti-CCP
antibodies were independently associated with RA. Anti-
EBNA-1 antibodies were neither correlated with the other
factors nor influenced disease risk, unlike in other auto-
immune conditions, such as MS. Despite some supporting
Figure 1 - Anti-EBNA-1 profiles in RA patients. A - profile according to anti-CCP (p=0.98); B - profile according to SE status (p=0.96);
C - profile according to smoking status (p=0.14).
Rheumatoid Arthritis Risk Factors
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evidence, the role of EBV in the development of RA remains
unclear and needs to be studied further. We emphasize the
importance of establishing the role of EBV in conjunction with
other factors involved in RA pathogenesis.
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